CAPTION: Philip Burchard, CEO of the Merz Group. (picture alliance / dpa)
The German pharmaceutical company Merz has invested around 40 million euros in its site in Dessau-Rosslau, in the eastern German state of Saxony-Anhalt. The money is to be used to build a filling plant and a multifunctional building, according to a spokeswoman for the Saxony-Anhalt Investment and Marketing Company (IMG) on Wednesday. In addition, the expansion will create 50 new jobs. IMG looks after the company in the state.
Merz has been manufacturing aesthetic and neurological products at the Biopharmapark Dessau-Rosslau since 2002. According to the spokesperson, the company is now focusing its manufacturing on "particularly high-turnover products," such as Xeomin, which is used for neurological movement disorders, and Bocouture, a product for aesthetic medicine.
The family-run company is headquartered in the city of Frankfurt am Main, and has several manufacturing sites in Germany and other countries.
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.
A single purchase
